Brief: Cerenis Therapeutics Reports Results of Phase II Study To Target Tumor In Patients With Esophageal Cancer

Abionyx Pharma SA

17/12/2018 17:08

Dec 17 (Reuters) - CERENIS THERAPEUTICS HOLDING SA
 CEREN.PA :
    * CERENIS THERAPEUTICS: FINAL RESULTS OF TARGET PHASE II
STUDY
DEMONSTRATE THE ABILITY OF CER-001, AN HDL MIMETIC, TO TARGET
TUMOR IN PATIENTS WITH ESOPHAGEAL CANCER
    * PRIMARY OBJECTIVE MET
    * RESULTS ARE CONSISTENT WITH PRECLINICAL STUDIES USING HDL
MIMETICS
    * NO SAFETY OR TOLERABILITY ISSUES WERE OBSERVED
    * SUSTAINED TUMOR LABELING SUPPORTS FUTURE USE OF HDL
MIMETICS TO
IMPROVE EFFECTIVE DELIVERY OF THERAPEUTIC AGENTS

Source text for Eikon:  urn:newsml:reuters.com:*:nBw5KgP9Ka
Further company coverage:  CEREN.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))